Structure announces promising Phase 2b aleniglipron data
Data showed up to 16.2% weight loss, no plateau, and low discontinuation; Phase 3 on track for Q3 2026.
See the latest news and media coverage for Structure. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biopharmaceutical company developing oral small molecule therapeutics
structuretx.comLast updated
In short: Structure Therapeutics advanced its oral obesity treatment aleniglipron toward Phase 3 trials following positive Phase 2 weight loss data.
Data showed up to 16.2% weight loss, no plateau, and low discontinuation; Phase 3 on track for Q3 2026.
The Phase 2b ACCESS study showed dose-dependent weight loss up to 16.2% at 56 weeks with low discontinuation, supporting Phase 3 initiation in Q3 2026.
Cash at $1.5B funds operations through 2028. Positive Phase 2 aleniglipron data with 16.3% weight loss. Phase 3 initiation on track for Q3 2026.
Lang brings over 15 years of biopharma experience in legal, strategy, and operations. He previously served at Metsera, Lyell Immunopharma, and Myovant.
H.C. Wainwright cuts Structure Therapeutics stock price target to $70...
AstraZeneca’s GLP-1 pill ... outperform a key competitor from Structure Therapeutics. The pharma’s asset, dubbed elecoglipron, showed “promising efficacy” in the Phase 2b VISTA study...
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the oversold stocks to buy right now. Structure Therapeutics reported positive Phase 2 results for its oral GLP-1...
June 5 (Reuters) - Structure Therapeutics said on Friday its experimental GLP-1 obesity pill did not show any signs of drug-induced liver injury, and patients...
Track Structure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Structure and other trending companies.